Propofol Cardioprotection for Type II Diabetics

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if an intravenous anesthetic with antioxidant properties will protect the heart of diabetic patients from injury while undergoing coronary bypass surgery.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of British Columbia
• Collaborator: Canadian Institutes of Health Research (CIHR)
• Treatments: Propofol

Criteria

Inclusion Criteria:

1. Patients with and without Type II Diabetes Mellitus

2. Hemodynamically Stable

3. Non urgent Coronary Bypass Grafting utilizing Cardiopulmonary Bypass

Exclusion Criteria:

1. Age less than 18 or greater than 80 years of age

2. refuse informed consent

3. Co-existing valvular heart disease

4. Acute or evolving myocardial infarction

5. hypersensitivity to propofol or formulation component

6. Use of NSAIDs, Vitamins C or E within 5 to 7 days of surgery